NEDD4 E3 ubiquitin ligases: Promising biomarkers and therapeutic targets for cancer

Accumulating evidence has demonstrated that NEDD4 E3 ubiquitin ligase family plays a pivotal oncogenic role in a variety of malignancies via mediating ubiquitin dependent degradation processes. Moreover, aberrant expression of NEDD4 E3 ubiquitin ligases is often indicative of cancer progression and correlated with poor prognosis. In this review, we are going to address association of expression of NEDD4 E3 ubiquitin ligases with cancers, the signaling pathways and the molecular mechanisms by which the NEDD4 E3 ubiquitin ligases regulate oncogenesis and progression, and the therapies targeting the NEDD4 E3 ubiquitin ligases. This review provides the systematic and comprehensive summary of the latest research status of E3 ubiquitin ligases in the NEDD4 subfamily, and proposes that NEDD4 family E3 ubiquitin ligases are promising anti-cancer drug targets, aiming to provide research direction for clinical targeting of NEDD4 E3 ubiquitin ligase therapy.

Automated summary

This review addresses the oncogenic role of NEDD4 E3 ubiquitin ligase family in various malignancies by mediating ubiquitin dependent degradation processes. It also discusses the association of NEDD4 E3 ubiquitin ligases expression with cancer progression, the signaling pathways and molecular mechanisms involved, and potential therapeutic targeting of these ligases. The review provides a systematic summary of the latest research status of E3 ubiquitin ligases in the NEDD4 subfamily and suggests that they are promising targets for anti-cancer drug development.